Background
Lung cancer is the most common cancer and the most common cause of death from cancer worldwide [
1]. Although smoking is a major risk factor for lung cancer, only 15% of smokers develop lung cancer [
2,
3], suggesting that different populations are more or less susceptible to carcinogens and that genetic factors probably play an important role in cancer aetiologies [
4].
Radiotherapy is an important treatment for cancers. However, 10% to 20% of cancer patients who undergo radiotherapy develop severe radiation-induced pneumonitis (RP), which influences their quality of life. Approximately half of patients with RP die [
5‐
7]. RP is a common dose-limiting toxicity of radiotherapy [
8]. Its risk factors include patient-related factors, such as gender, smoking and pulmonary function, and treatment-related factors, such as the radiation dose and irradiated lung volume, and whether surgery or chemotherapy was performed [
9‐
11]. However, these factors do not sufficiently explain the wide variations observed in susceptibility among patients. Recent studies have shown that variation in individual susceptibility to cancers and RP is affected by gene polymorphisms, especially those affect DNA repair [
12].
The ataxia-telangiectasia mutated (ATM) gene is one such DNA repair gene.
ATM plays an important role in the repair of DNA damage, especially DNA double-strand breaks (DSBs) [
13,
14]. DSBs can lead to genetic information loss, harmful gene variations and chromosomal rearrangements, which can result in the development of cancer [
15]. The ATM protein is a phosphoinositide 3-kinase (PI-3 kinases) [
13]. Once an exogenous injury, such as ionizing radiation, induces DSBs, the ATM protein is activated via autophosphorylation. It can then phosphorylate dozens of downstream substrates, many of which are key factors in DNA repair, apoptosis, cell cycle arrest and gene regulation [
16,
17]. The affected genes include the checkpoint protein RAD50, cycle checkpoint kinase (CHK2), tumor suppressor P53, breast cancer protein 1 (BRCA1), the repair protein
Nijmegen breakage syndrome 1 (NBS1), and the oncogenic protein murine double minute 2 (MDM2) [
18,
19]. Polymorphisms in
ATM may influence the structure and function of the protein, leading to defects in the activation of cell cycle checkpoints, DNA DSB repair, and cell apoptosis. Additionally,
ATM gene mutations may alter the radiosensitivity of cells [
8,
20,
21]. The development of cancers and radiation- induced side effects, including pneumonitis, is often linked to these abnormal cells [
20,
22].
Previous studies have shown that several
ATM gene polymorphisms (e.g., rs664143, rs664677, rs189037, and rs609429) may be associated with susceptibility to lung cancer [
23‐
25], and that others (e.g., rs189037) may be associated with RP risk [
26,
27]. However, the results of those studies have been inconsistent, and previous meta-analyses were not comprehensive. Therefore, we conducted this comprehensive meta-analysis to evaluate the association between
ATM gene polymorphisms and both susceptibility to lung cancer and the risk of RP in lung cancer patients treated with radiotherapy. To the best of our knowledge, the current study is the most comprehensive analysis of the relationship between susceptibility to lung cancer and
ATM gene polymorphisms and the first meta-analysis to evaluate the association between RP risk and
ATM gene mutations.
Methods
Eligible studies
We searched the PubMed, Embase, China National Knowledge Internet (CNKI) and Wanfang databases to identify studies that investigated the association between ATM gene polymorphisms and lung cancer as or RP in lung cancer patients treated with radiotherapy (the last search was performed on Dec.10, 2015) using the following search terms: “ATM” and “cancer” or “lung cancer” or “Lung Neoplasms” and “polymorphism” or “variant”; “ATM” and “radiation pneumonia” or “radiation pneumonitis” and “polymorphism” or “variant”. The references listed in the resulting articles were also searched to identify additional relevant articles.
The following were the inclusion criteria for studies in our meta-analysis: (1) case-control studies focused on ATM polymorphisms and lung cancer susceptibility or RP risk, (2) data on genotype frequencies were available for both the cases and controls, (3) published in English or Chinese, and (4) the genotype distribution of the control group was in accordance with Hardy-Weinberg equilibrium. The following exclusion criteria were applied: (1) no control group, (2) duplication of a previous study, and (3) no usable data on genotype frequency.
Two authors independently extracted the data from all eligible publications. The following information was extracted from each relevant study: the first author’s name, country of origin, publication year, ethnicity of the study individuals, cancer type, genotyping methods, sample size and genotype frequencies.
Statistical analysis
All statistical analyses were performed by Stata 13.0. The strength of the association between an ATM polymorphism and lung cancer or RP was measured by odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was evaluated by the chi-squared (x2) and I-squared (I2) test. If P > 0.10 and I2 < 50%, no heterogeneity was detected among the studies, and the OR was calculated by the fixed-effects model. Otherwise, the random-effects model was used. To evaluate ethnicity-specific effects, a subgroup analysis was performed by ethnicity group. The potential publication bias was assessed by funnel plots, Begg’s test and Egger’s test.
Discussion
In the present meta-analysis, we found that there were significant associations between lung cancer risk and rs189037, rs664677 and rs664143. Additionally, we found that the rs189037 A allele was significantly associated with the risk of RP. Significant heterogeneity was found in two of the genetic models used to evaluate the risk of RP. This may be because different diagnostic standards were used in different studies. Fortunately, the genetic models identified in our study that did produce significant associations results showed no significant heterogeneity. No significant publication bias was found in polymorphisms that were covered by at least five studies.
ATM rs189037 is located in the 5’UTR of the promoter region of the ATM gene [
36]. This SNP can bind to the activator protein 2α (AP-2α), which represses
ATM transcription, and different genotypes have different affinities for this transcription factor [
37]. As some studies have suggested, the AA genotype of
ATM rs189037 increases the risk of oral [
38] and breast cancer [
39]. Furthermore, this mutation may be associated with the risk of thyroid carcinoma [
40].
ATM rs664143 is located in the protein binding motifs that serve as binding sites for intronic splicing enhancers or repressors, suggesting the possibility that this site may be involved in the exon 61 splicing process and that it may cause inaccurate splicing [
24]. The precise roles of rs664677 and rs609429 remain unclear [
41]. The former loci may participate in regulating RNA splicing and maintaining RNA stability [
41]. A study performed in Korea showed that the rs664677 CC genotype might be associated with a higher risk of breast cancer [
42]. However, rs664677 was not associated with either papillary thyroid carcinoma [
43,
44] or pancreatic cancer [
45]. Other studies failed to find a significant association between this loci and the risk of cancers, such as breast cancer [
46,
47]. DNA repair pathways are activated after DNA damage, especially DNA DSBs [
20]. Individuals with impaired DNA repair pathways have high sensitivity to radiation exposure and therefore a higher risk of lung cancer and RP [
8,
20]. Previous studies have suggested that the
ATM gene plays a critical role in DNA damage repair and thereby affects the risk of lung cancer and RP. We performed this meta-analysis because the results of previous studies were inconclusive.
Several limitations of the current analysis should be mentioned. First, we failed to conduct a subgroup analysis to evaluate the effects of other factors, such as gender, smoking status or histological subtypes, because insufficient data was available. Second, we included only articles published in either English or Chinese, resulting in potential publication bias, despite the fact that the Egger’s test and funnel plots showed that there was no publication bias. Despite these limitations, the likelihood of bias was minimized throughout the process because we used a detailed protocol that included study identification, data selection and the statistical analysis, and we controlled publication bias. Therefore, we believe that our results are reliable. Additionally, most polymorphisms and studies of the ATM gene are included in this study. It is also the first meta-analysis to evaluate the association between ATM gene polymorphisms and the risk of RP.
Conclusions
In conclusion, in this meta-analysis, we showed that the ATM rs189037 polymorphism is significantly associated with lung cancer and the risk of RP after radiotherapy. The ATM rs664677 and ATM rs664143 polymorphisms were significantly associated with lung cancer susceptibility, while rs609429 was not. More well-designed studies that include larger sample sizes should be performed in the future to further evaluate the association between the ATM gene and cancers.